Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Phase 2 Completed 41 enrolled Fox Chase Cancer Center Bristol-Myers Squibb · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.

Timeline

Start: 2006-08
Primary completion: 2010-07
Completion: 2012-09

Publications

Results Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012 Oct 1;30(28):3545-51. doi: 10.1200/JCO.2012.41.9572. Epub 2012 Aug 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	80 mg/m2	Intravenous

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Summary

Timeline

Publications

Drugs

Indications